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Abstract
The aim of this study was to evaluate whether L-Arginine (L-Arg) supplementation modifies nitric oxide (NO) system and
consequently aquaporin-2 (AQP2) expression in the renal outer medulla of streptozotocin-diabetic rats at an early time
point after induction of diabetes. Male Wistar rats were divided in four groups: Control, Diabetic, Diabetic treated with L-
Arginine and Control treated with L-Arginine. Nitric oxide synthase (NOS) activity was estimated by [14C] L-citrulline
production in homogenates of the renal outer medulla and by NADPH-diaphorase staining in renal outer medullary tubules.
Western blot was used to detect the expression of AQP2 and NOS types I and III; real time PCR was used to quantify AQP2
mRNA. The expression of both NOS isoforms, NOS I and NOS III, was decreased in the renal outer medulla of diabetic rats
and L-Arg failed to prevent these decreases. However, L-Arg improved NO production, NADPH-diaphorase activity in
collecting ducts and other tubular structures, and NOS activity in renal homogenates from diabetic rats. AQP2 protein and
mRNA were decreased in the renal outer medulla of diabetic rats and L-Arg administration prevented these decreases.
These results suggest that the decreased NOS activity in collecting ducts of the renal outer medulla may cause, at least in
part, the decreased expression of AQP2 in this model of diabetes and constitute additional evidence supporting a role for
NO in contributing to renal water reabsorption through the modulation of AQP2 expression in this pathological condition.
However, we cannot discard that another pathway different from NOS also exists that links L-Arg to AQP2 expression.
Citation: Ortiz MC, Albertoni Borghese MF, Balonga SE, Lavagna A, Filipuzzi AL, et al. (2014) Renal Response to L-Arginine in Diabetic Rats. A Possible Link
between Nitric Oxide System and Aquaporin-2. PLoS ONE 9(8): e104923. doi:10.1371/journal.pone.0104923
Editor: Robert A. Fenton, Aarhus University, Denmark
Received March 18, 2014; Accepted July 15, 2014; Published August 11, 2014
Copyright:  2014 Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This study was partially supported by grants: UBACYT B087 and UBACYT Number 20020110200353 from Universidad de Buenos Aires, (Buenos Aires,
Argentina). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: mmajow@ffyb.uba.ar
Introduction
The imbalance of different vasoactive substances contributes to
the development and progression of complications in Diabetes
Mellitus (DM). For example, nitric oxide (NO) synthesis is found to
be abnormal [1] and several studies have provided evidence
involving diabetes as a state of renal NO deficiency [2].
L-arginine (L-Arg) is a semi-essential amino acid and also the
main source for the generation of NO via nitric oxide synthase
(NOS) [3]. The kidney plays a key role in Arg metabolism and the
enzymes that participate in L-Arg synthesis are down-regulated in
DM, impairing L-Arg production quite early before any significant
structural damage is evident, thus contributing to the resulting NO
deficiency [4]. It has been also demonstrated that diabetic animals
have increased hepatic Arg degradation resulting in reduced
plasma Arg levels, which limit the renal medullary NO levels [5].
On the other hand, serum levels of asymmetric dimethylargi-
nine (ADMA), an endogenous inhibitor of NOS, are increased in
both type 1 and type 2 DM, which leads to a decrease in NO
production and thus contributes to diabetic complications such as
nephropathy and retinopathy [6].
As DM is associated with reduced plasma levels of Arg, L-Arg
supplementation may be effective in the improvement of the
endothelial and renal function in diabetic patients [7].
The three NOS isoforms are expressed in the kidney; these
isoforms are neuronal NOS (nNOS; NOS I); endothelial NOS
(eNOS; NOS III) and inducible NOS (iNOS; NOS II), being NOS
I and NOS III the main isoforms involved in tubular sodium and
water transport regulation [8]. The renal medulla, where the three
isoforms are expressed, has a greater ability to generate NO than
the renal cortex [9].
Different studies have shown an altered expression of multiple
medullar water and sodium transporters in the kidney of DM I
rats, being aquaporin-2 (AQP2) one of these transporters [10].
AQP2, a water channel mainly regulated by vasopressin, is
localized in the principal cells of the collecting ducts and
constitutes the final checkpoint for renal water reabsorption
[11]. In addition to vasopressin, several other factors affect AQP2
transcription. Feraille et al. recently described a novel role for
NADPH oxidase 4 (NOX4) in regulating AQP2 abundance. They
proposed that NOX4-mediated production of reactive oxygen
species (ROS) may enhance V2R-cAMP-PKA signaling by
attenuating phosphodiesterase (PDE) activity [12]. It is interesting
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to note that in physiological conditions renal tubular NOX4
produces low amounts of ROS that stimulate intracellular signal
pathways, but in a rodent model of streptozotocin (STZ)-induced
type 1 diabetes, renal expression of NOX4 is increased, and this is
associated with ROS-induced renal damage [13].
There are controversial findings about AQP2 expression in
diabetes induced by STZ. Some studies have shown an increase in
both AQP2 expression and translocation in the renal medulla [14],
whereas others have shown either a decrease [15] or no changes
[16] in the expression of the protein. These results have all been
found after the first two weeks of development of diabetes and
there are no studies showing AQP2 expression at an early time
point after the induction of diabetes.
There is evidence that NO can modulate AQP2 translocation to
the plasma membrane [17–19], but there is very scarce
information about NO contribution to AQP2 expression. Boone
et al., using mpkCCD cells, demonstrated that the activators of the
cGMP pathway ANP, L-Arg and 8-Br-cGMP do not induce
AQP2 expression in vitro by themselves but they induce AQP2
translocation to the apical membrane. However, when they tested
the effect of 1-desamino-8-D-arginine vasopressin (dDAVP)
combined with activators of the cGMP pathway on AQP2
expression in the mpkCCD cells, only L-Arg seemed to enhance
AQP2 expression. They suggested that the beneficial effect of
compounds of the cGMP pathway to relieve nephrogenic diabetes
insipidus may be improved when combined with agents that
stimulate AQP2 expression [20].
It has been shown that both mRNA and protein of all NOS
isoforms are increased in the renal medulla of rats with four days
of water deprivation [21], which suggests that the intrarenal NO
system is very important in the control of body volume balance. In
addition, it has been suggested that endogenous NO produced
from NOS I may participate in the regulation of water
reabsorption by the collecting duct [22].
On the other hand, Morishita et al. have shown that KO mice
lacking all NOS isoforms develop nephrogenic diabetes insipidus
with a reduced antidiuretic response to exogenous vasopressin,
accompanied by impaired renal cAMP production, a defective
membrane expression of AQP2 water channel, and tubuloglo-
merular lesion [23]. These antecedents prompted us to evaluate
whether L-Arg supplementation modifies NOS I and NOS III
expression and activity and consequently AQP2 expression in the
renal outer medulla of STZ-induced diabetic rats at an early time
point. We intended to find new evidence supporting a role for the
NO system in AQP2 expression.
Our hypothesis was that AQP2 expression is already decreased
in diabetic animals at an early time point after induction of
diabetes and that L-Arg supplementation improves NO produc-
tion, which, in turn, increases AQP2 expression.
Materials and Methods
Chemicals
The reagents used in western blot analysis were from Bio Rad
(CA, USA). All other chemicals and reagents, unless otherwise
indicated, were from Sigma-Aldrich Corporation (St. Louis, MO,
USA).
Animals and treatments
All experimental protocols were performed in accordance with
the Guide for the Care and Use of Laboratory Animals (National
Institutes of Health, Publication No. 85-23, Revised 1996) and
Regulation No. 6344/96 of Argentina’s National Drug, Food and
Medical Technology Administration (ANMAT). Experimental
procedures were approved by the Ethics Committee of the School
of Pharmacy and Biochemistry, University of Buenos Aires.
Male Wistar rats weighing 250–300 g were purchased from the
facilities of the School of Pharmacy and Biochemistry of the
University of Buenos Aires (Buenos Aires, Argentina) and were
housed in a humidity and temperature-controlled environment
with an automatic 12-hour light-dark cycle. They were fed
standard rat chow and provided tap water ad libitum up to the day
of the experiments. The animals were divided in four groups:
Control, Diabetic, Diabetic treated with L-Arg, and Control
treated with L-Arg. Diabetes was induced by a single intraperi-
toneal injection of STZ in a dose of 70 mg/kg of body weight
diluted in citrate buffer [24]. Controls were injected with citrate
buffer alone. L-Arg was administered to the diabetic treated and
control treated groups in the drinking water in a dose of 622 mg/
kg/day [25], simultaneously with the induction of diabetes. The
concentration of L-Arg in the drinking water was adjusted
considering the drinking water intake from the previous day for
each animal to eliminate changes due to different intakes.
Four days after the induction of diabetes, the animals were
anesthetized with ether and blood samples were immediately
obtained by cardiac puncture until exsanguinations and all efforts
were made to minimize suffering.
Four days were chosen because at this early time, the animals
already manifest hyperglycemia and polyuria and it is a time long
enough to allow changes in protein abundances but too short to
lead to large effects resulting from diabetic nephropathy. Besides,
there are no results regarding AQP2 expression at this early time
point after the onset of diabetes. On the other hand, long term
arginine supplementation is ineffective in improving NOSIII
activity and even it may be detrimental [26].
Glycemia was measured in blood samples by the glucose
oxidase method (Betachek, National Diagnostic Products, Sidney,
Australia). The diabetic condition was characterized by a clear
hyperglycemic state, loss of body weight and increased diuresis
four days after STZ injection. STZ-treated animals with glucose
plasma levels below 11 mmol/l were not included in the
experimental protocol.
Determinations in the 24-hour metabolic cage studies
Twenty four-hour urine samples were collected using metabolic
cages. Animals were allowed to acclimatize to metabolic cages for
two days and then fasted for 24 h before the collection of urine to
avoid differences in plasma glucose concentration and NOx
excretion due to different food intake. Urine samples (24 h) were
analyzed for total protein by a turbidimetric method using
trichloroacetic acid as previously described [27]. Urine analysis
for glucose and ketones was carried out using reactive strips (Keto-
Diastix Bayer Diagnostics S.A., Argentina). Urine osmolality was
measured with an osmometer (OSMETTE, Precision Systems
Inc., MA, USA) and expressed as osmolar excretion rate. Urine
volume was measured gravimetrically. Kinetic determinations of
serum and urinary creatinine concentration were evaluated using
a kit provided by Wiener (Wiener Lab., Rosario, Argentina).
Tissue processing for Western blot analysis
Immediately after the animals were sacrificed, their kidneys
were isolated and the outer medulla was dissected and homoge-
nized at 3.000 rpm in an appropriate buffer (250 mmol/l sucrose,
1 mmol/l EDTA, 0.1 mmol/l PMSF and 10 mmol/l Tris-ClH),
pH 7.6. Large tissue debris and nuclear fragments were removed
by a low-speed spin (1000 g, 10 min, 4uC). Protein concentration
was measured using BCATM Protein Assay Kit (Pierce, Rockford,
IL, USA). Absorbances for protein concentration measurements
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were read using an RT-2100C microplate reader (Rayto, China)
at 560 nm.
Western blots of AQP2 and NOS isoforms
Western blot analysis was used to identify AQP2, NOS I and
NOS III. Blots were incubated overnight at 4uC with the AQP2
antibody (rabbit anti-rat AQP2; Santa Cruz Biotechnology, Inc.,
CA, USA) diluted in blocking solution (1:500), or with NOS I or
NOS III antibodies (rabbit anti-rat; diluted 1:1000; BD Trans-
duction Laboratories, NJ, USA). Beta-tubulin was used as loading
control (rabbit anti-rat beta-tubulin; Abcam Inc., Cambridge, MA,
USA). The membranes were then incubated with a biotinylated
donkey anti-rabbit IgG (1:2.500) (Jackson ImmunoResearch,
Baltimore Pike, Pa., USA). Blots were stained using Vectastain
ABC kit and DAB substrate kit for peroxidase (both from Vector
Laboratories Inc. Burlingame, CA, USA). The AQP2 antibody
recognizes a 28-kDa band corresponding to unglycosylated AQP2
and bands between 35–40 kDa representing glycosylated forms of
the protein. The NOS I antibody recognizes a 155-kDa band and
the NOS III antibody detects a 140-kDa band.
The relative protein levels were determined by analyzing the
bands with Gel Pro Analyzer 3.1 for Windows and protein
expression was calculated as the ratio of AQP2, NOS I or NOS III
to beta-tubulin.
Real-time PCR for AQP2
Total RNA was isolated using the SV total RNA Isolation
System (Promega, Madison, WI, USA). Total RNA was reverse
transcribed to cDNA using a high capacity reverse transcription kit
(A&B, CA, USA). For real-time detection of AQP2 transcripts and
the reference gene (GAPDH), MezclaReal (Real Time PCR
commercial mixture from Biodynamics, Argentina) and specific
primers [28] were used. The normalized gene expression method
(2–DDCT) for the relative quantification of gene expression was
used. The difference in the cycle threshold (CT) for AQP2 and
GAPDH for the control untreated rats was substracted from the
difference in the CT for AQP2 and GAPDH for each of the
experimental groups. The following formula was applied:
DDCT= (CTAQP22CTGAPDH)experimental2(CT AQP22CT
GAPDH)control untreated rats [29].
The real-time PCR started at 94uC for 2 min and was followed
by 35 thermal cycles at 94uC for 15 s, 58uC for 35 s and 72uC for
30 s.
Histochemistry
Tissues were processed using the NADPH-diaphorase
(NADPH-d) histochemical method according to Rothe et al.
[30]. NADPH-d staining is widely used to detect NOS-containing
cells in neural and non-neural tissues. With the appropriate
fixation procedure, this method can detect cells containing any of
the NOS isoforms [31]. The NADPH-d reaction can be used to
monitor NOS activity at a cellular level of resolution [32]. The
kidneys were fixed with 4% paraformaldehyde in 0.1 M phosphate
buffer pH 7.4, then the tissues were cryoprotected with sucrose,
frozen, sectioned at 14 mm on a criostate and mounted on gelatin-
coated glass slides. Briefly, sections were simultaneously incubated
for 1 h at 37uC in the same reaction mixture containing 0.1% b-
NADPH and 0.02% nitrobluetetrazolium diluted in 0.1 M
phosphate buffer with 0.3% Triton X-100. Then, sections were
mounted in PBS/glycerol (1:3). Observation, optical density (OD)
measurement and photography were made with a Nikon
Alphaphot-2 YS2 coupled to a SONY camera Model NuSSC-
DCSOA. NADPH-d-stained cells from the different groups were
measured by a computer image-analysis program (Scion Image).
Each set of OD measurements (control and experimental groups)
was performed blindly and under similar conditions of light, gain,
offset and magnification. After automatic normalization of gray-
scale, the same interactive delineation and contrast enhancement
of all images was performed. To obtain each value, the program
calculates the mean of different OD values obtained in the same
renal tubule. This process was done in different renal tubules of
the same section and different sections of the same kidney.
NO metabolites measurement
The concentration of NO metabolites (nitrites and nitrates,
NOx) in urine samples was determined according to the procedure
described by Verdon et al. [33].
Nitric oxide synthase activity
Total NOS activity in the renal outer medulla was determined
on the basis of the rate of L-[14C] citrulline formation from [14C]
L-Arg, as described previously [34].
Specific NOS activity was assessed in the presence of 1024 M L-
nitro-arginine-methyl-ester (L-NAME). NO production (measured
as pmol of [14C] L-citrulline) in each tube was normalized to the
weight of the tissue slices incubated with the substrate for equal
periods of time and expressed as pmol/g wet weight/min. Total
NOS activity was defined as the [14C] L-Arg-to-[14C] L-citrulline
conversion that was inhibited by the non-selective NOS inhibitor
L-NAME (1024 mol/L).
Statistics
Results are expressed as the mean 6 SEM. Two-way ANOVA
was used to analyze the data, where one factor was the diabetes
(control or diabetic rats) and the other the treatment with L-Arg
(treated or untreated rats). The main effect of each factor was
tested as well as the interaction within both factors. Bonferroni’s
post-test was used for multiple comparisons when interaction was
statistically significant. When the interaction was found to be
statistically significant, the main effect of each factor was not
informed (as each factor is influenced by the other) and simple
main effects were informed separately (e.g. the effect of L-Arg on
control rats and the effect of L-Arg on diabetic rats, separately).
The analysis was performed using Graph Pad Prism version 5.0 for
Windows, Graph Pad Software (San Diego, CA, USA). The null
hypothesis was rejected when p,0.05.
Results
Effects of L-Arg administration on some general and
renal parameters
The results of L-Arg administration on some general and renal
parameters are shown in Table 1.
The body weight of diabetic rats (untreated and treated with L-
Arg) decreased when compared with control groups (untreated
and treated with L-Arg, p,0.001). Although the kidney weights of
the different groups showed no changes (data not shown), the
kidney weight/body weight ratio of the diabetic animals increased
due to the decrease in their body weights (p,0.01). These results
provide evidence that L-Arg administration did not prevent the
loss of weight in diabetic animals.
On day four, blood glucose was increased to the same extent in
both diabetic groups. Urinary glucose (mmol/l) was undetectable
in control groups, whereas it was 33.369.4 in diabetic untreated
rats and 30.569.1 in diabetic rats treated with L-Arg. These
results indicate that L-Arg administration did not correct the levels
of blood and urinary glucose in diabetic rats, although it partially
corrected the value of urinary ketones.
Renal Effects of L-Arginine in Diabetic Rats
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Urinary volume (ml/24 h) and Osmolar excretion rate
increased in diabetic rats and were partially corrected by L-Arg
administration, although the values obtained in diabetic rats
treated with L-Arg were still higher than those of control and
control treated with L-Arg rats.
Urinary protein excretion and creatinine clearance showed no
statistically significant changes in any of the groups. L-Arg
administration to control rats did not modify any of the
parameters tested.
L-Arg improves urinary NO metabolites production and
NADPH-d activity in some structures of the renal outer
medulla in diabetic rats
Table 1 shows the urinary excretion of NO metabolites, which
traditionally was considered to reflect systemic NO production
[35]. However, recently, Hyndman et al. showed that urinary
excretion of NO metabolites should be considered a measure of
collecting duct-derived NO production [36]. The excretion was
normalized to urinary creatinine to minimize possible confounding
effects of urinary dilution. The results showed an interaction
between the effects of diabetes and L-Arg administration (p,0.05).
NOx (nmol/mg creatinine) significantly decreased in the diabetic
untreated group compared to the control untreated group. L-Arg
administration produced an increase in NOx in diabetic rats but
not in control rats.
Table 2 and figures S1 and S2 show the effect of L-Arg on
NADPH-d activity in the renal outer medulla of control and
diabetic rats. NADPH-d activity (expressed as arbitrary units of
optical density) was decreased in the collecting ducts of the diabetic
rats present in the outer stripe of the outer medulla and in the thick
ascending limb of Henle’s loop present in the inner stripe of the
outer medulla, whereas in the collecting ducts of the inner stripe of
the outer medulla NADPH-d activity showed a trend (p,0.1) to
decrease. L-Arg administration to diabetic rats improved
NADPH-d activity in proximal tubules from the outer stripe, in
the thick ascending limb of Henle’s loop from the inner stripe and
in the collecting ducts from the inner and outer stripe of the outer
medulla. On the other hand, L-Arg administration to control rats
enhanced NADPH-d staining only in the collecting ducts from
both inner and outer stripe.
L-Arg improves NO synthase activity in the renal outer
medulla of diabetic and control rats
Figure 1 shows that NOS activity expressed as pmol [14C] L-
citrulline/g tissue/min dramatically decreased in the renal outer
medulla of the diabetic rats. On the other hand, L-Arg
administration to the animals prevented the decrease in NOS
activity in diabetic rats, and enhanced NOS activity in control rats
(Fig. 1).
L-Arg does not prevent the decreased expression of NOS
I and NOS III in the renal outer medulla of diabetic rats
Figure 2 and 3 show that the expression of both NOS I and
NOS III was decreased in the renal outer medulla of diabetic
untreated rats. This result may explain, at least in part, the
decreased NADPH-d activity in most renal tubules and the
decreased NOS activity measured as [14C] L-citrulline production
in the diabetic rats. On the other hand, L-Arg administration to
diabetic rats did not prevent the decreased expression of NOS I
and NOS III (Fig. 2 and 3).
L-Arg treatment prevents the decrease in AQP2 protein
expression and mRNA in the renal outer medulla of
diabetic rats
Figures 4 and 5 show that both AQP2 protein (arbitrary units of
total AQP2/tubulin ratio) and mRNA expression were decreased
in the renal outer medulla of diabetic untreated rats.
L-Arg administration to the diabetic rats prevented both the
decrease in AQP2 mRNA and protein expression, showing values
similar to those of the control group for the protein and even
greater for the mRNA. It is interesting to note that L-Arg
administration increased AQP2 expression to the same extent in
control and diabetic rats. Meanwhile, the increase in AQP2
mRNA due to L-Arg administration is higher in diabetic rats than
in control rats (Figs. 4 and 5).
Table 1. Summary of some general and renal parameters in control and diabetic rats.
C D C+A D+A
Initial body weight (g) 307.3611.1 320.6621.7 311.2612.0 327.2620.5
Final body Weight (g) 355.1617.2 270.1619.4*** 347.9622.5 275.6616.1###
Kidney weight/body weight (mg/g) 3.760.2 5.460.4** 4.260.4 5.160.5##
Blood glucose (mmol/l) 5.660.5 16.161.7*** 5.060.4 15.761.2###
Urinary volume (ml/24 h) 10.361.1 15.961.4* 9.061.2 12.961.4#
Osmolar excretion rate (mOsm/24 h) 8.561.1 18.262.5** 9.561.6 16.363.2##
Urinary glucose (mmol/l) Undetectable (0.0060.00) 33.369.4*** Undetectable (0.0060.00) 30.569.1###
Urinary ketones (mmol/l) Undetectable (0.0060.00) 0.7860.19*** Undetectable (0.0060.00) 0.2960.12###
Urinary proteins (mg/24 h) 6.460.4 6.961.6 6.760.3 4.760.5
Creatinine clearance (ml/min) 1.0960.15 1.3360.12 0.9360.11 1.1260.14
NOx (nmol/mg creatinine) 10.661.3 5.060.6* 11.860.7 13.962.4&&&
C: control rats; D: diabetic untreated rats; D+A: diabetic rats treated with L-Arg; C+A: control rats treated with L-Arg. Results are expressed as the mean 6 SEM (n = 6).
Two-way ANOVA showed a statistically significant interaction (p,0.05) between the effects of Diabetes and L-Arg treatment on NOx urinary excretion. There was no
interaction between the effects of Diabetes and L-Arg treatment on the other parameters. Diabetes had a significant overall effect on Final body weight (p,0.001),
Kidney weight/body weight (p,0.001), Blood glucose (p,0.001), Urinary volume (p,0.05), Osmolar excretion rate (p,0.01), Urinary glucose (p,0.001) and Urinary
ketones (p,0.001). L-Arg had no significant effect on any of the parameters tested. *p,0.05 vs. C; **p,0.01 vs. C; ***p,0.001 vs. C; #p,0.05 vs. C+A; ##p,0.01 vs. C+A
###p,0.001 vs. C+A; &&&p,0.001 vs. D.
doi:10.1371/journal.pone.0104923.t001
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The results of AQP2 western blot were corroborated by
immunohistochemistry (Figs. S3 and S4), where we showed that
AQP2 expression decreased in diabetic rats and that L-Arg
treatment increased AQP2 expression in both control and diabetic
rats. Additionally, in Figure S4 it can be observed that L-Arg
stimulated AQP2 translocation to apical membrane of the
principal cells of the collecting ducts, being this effect enhanced
in diabetic rats.
Discussion
In diabetes, abnormalities in NO production impact on renal
structure and function [37]. Our study shows that NO production,
NOS I and NOS III expression, NOS activity and AQP2
expression are decreased in the renal outer medulla of rats at an
early stage of STZ-induced diabetes.
Diabetes is associated with vascular oxidative stress, the
activation of NADPH oxidase, and the uncoupling of NOS III
[38]. However, results regarding the levels of NOS expression in
the kidney of diabetic rats are variable. Some authors have
reported an increased expression of the different NOS isoforms
[9], whereas others have found a decreased expression [39]. In the
present work, we found that the expression of both NOS I and
NOS III was decreased in the renal outer medulla of the diabetic
rats and that L-Arg administration did not prevent this decrease.
Data regarding the impact of L-Arg on the regulation of the
expression of genes and proteins for all NOS isoforms are scarce.
Rusai et al. have demonstrated that L-Arg supplementation for
seven days in rats with a model of renal ischemia increased the
mRNA expression of all three NOS isoforms, but increased only
NOS II protein levels [40].
On the other hand, we also found an important decrease in
NOS activity in the renal outer medulla of the diabetic rats. L-Arg
administration prevented the decrease in NOS activity in diabetic
animals and increased the activity in control animals.
It is known that NOS activity is regulated by both post-
transcriptional and post-translational events and that they may be
deranged in pathophysiological states like diabetes [41]. For
Table 2. Effect of L-arginine on NADPH-diaphorase activity in the renal outer medulla of control and diabetic rats.
C D C+A D+A
PT (OS) 0.23560.006 (n = 32) 0.24160.007 (n = 40) 0.24460.004 (n = 45) 0.29860.009###&&& (n = 25)
CD (OS) 0.17160.003 (n = 24) 0.14260.008** (n = 15) 0.20960.005*** (n = 24) 0.27660.007###&&& (n = 31)
CD (IS) 0.15760.007 (n = 16) 0.14760.004 (n = 22) 0.18760.003*** (n = 19) 0.15860.004###& (n = 16)
THAL (IS) 0.25560.004 (n = 30) 0.21060.002*** (n = 32) 0.25860.003 (n = 32) 0.22160.002###& (n = 26)
C: control rats; D: diabetic untreated rats; D+A: diabetic rats treated with L-Arg; C+A: control rats treated with L-Arg. PT: proximal tubule; CD: collecting duct; THAL: thick
ascending limb of Henle; OS: outer stripe; IS: inner stripe. NADPH-d staining values are expressed as optical density. Results are expressed as the mean 6 SEM; ‘‘n’’
represents the total number of renal tubules analyzed. At least four animals of each group were used. Two-way ANOVA showed a statistically significant interaction
between the effects of Diabetes and L-Arg treatment on NADPH-diaphorase activity in PT (p,0.001), CD (OS) (p,0.001), CD (IS) (p,0.05) and THAL (p,0.05).
Bonferroni’s post-tests are showed in the table: **p,0.01 vs. C; ***p,0.001 vs. C; ###p,0.001 vs. C+A; &p,0.05 vs. D; &&&p,0.001 vs. D.
doi:10.1371/journal.pone.0104923.t002
Figure 1. NOS activity measured as pmol [14C] L-citrulline/g
tissue/min. Two-way ANOVA showed no statistically significant
interaction between the effects of Diabetes and L-Arg treatment on
NOS activity. The effects of Diabetes and L-Arg were considered
extremely significant (p,0.001). ***p,0.001 vs. control untreated rats;
###p,0.001 vs. control rats treated with L-Arg; &&&p,0.001 vs. diabetic
untreated rats. Data are mean 6 SEM (n = 8).
doi:10.1371/journal.pone.0104923.g001
Figure 2. NOS I expression in homogenates of the renal outer
medulla. A. Representative western blot analysis of NOS I (155 kDa
band) and tubulin (50 kDa band) in the renal outer medulla; B. NOS I
expression indicated as NOS I/tubulin ratio fold change from control
untreated rats. Two-way ANOVA showed no statistically significant
interaction between the effects of Diabetes and L-Arg treatment on
NOS I expression. The effect of Diabetes was considered very significant
(p,0.01), the effect of L-Arg was not significant. **p,0.01 vs. control
untreated rats, ##p,0.01 vs. control rats treated with L-Arg. Data are
mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0104923.g002
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example, it has been shown that hyperglycemia inhibits NOS III
activity by post-translational modification in the Akt site [42].
Bearing in mind that L-Arg did not affect plasma glucose levels, it
is unlikely that L-Arg administration prevented the glycosylation of
NOS isoforms. On the other hand, hyperglycemia has been
associated with increased formation of ROS [43] and it has been
reported that L-Arg enhances enzymatic antioxidants in diabetic
rats in both the liver and the kidney [44]. So, it may be that L-Arg
supplementation enhances NOS activity decreasing ROS forma-
tion. This may explain the increase in NOS activity in the diabetic
rats, but not in the control rats, which led us to think that L-Arg is
more probably acting as an allosteric activator of the enzyme in
both control and diabetic rats [45].
Regarding NOx excretion, we showed that there was a
significant decrease in the diabetic untreated rats and that the
decrease was prevented by L-Arg supplementation. This result
correlates with that obtained in NOS activity. However, L-Arg
supplementation to control rats only showed a tendency to
increase NOx, but this increase was not significant. This may be
explained by the fact that NOS activity was measured in
homogenates of the renal outer medulla, meanwhile NOx
excretion may be reflecting NO systemic production and not only
NO renal production.
The early stages of diabetic nephropathy are associated with
abnormalities in glomerular hemodynamic as well as with
alterations in the renal tubular function. It is known that NO
modulates sodium transport along the different segments of the
nephron [46], but there is less evidence about the effect of the NO
system on water transport.
Our results show that in early diabetes, both AQP2 protein and
mRNA are decreased and that L-Arg administration prevented
these decreases in the renal outer medulla of diabetic rats.
This is in accordance with a previous work of our laboratory,
where we showed that AQP2 is down regulated in the renal
medulla of rats made hypertensive by chronic inhibition of NOS
[27]. Besides, we have recently demonstrated a synergistic effect of
NO and NFATc (nuclear factor of activated T cells) promoting an
increase in AQP2 mRNA and protein in mouse papilla and
activation of the AQP2 promoter in kidney-derived cells [47].
In opposition to us, a recent work showed an up regulation of
glycosylated AQP2 in STZ-diabetic rats and found that the
Figure 3. NOS III expression in homogenates of the renal outer
medulla. A. Representative western blot analysis of NOS III (140 kDa
band) and tubulin (50 kDa band) in the renal outer medulla; B. NOS III
expression indicated as NOS III/tubulin ratio fold change from control
untreated rats. Two-way ANOVA showed no statistically significant
interaction between the effects of Diabetes and L-Arg treatment on
NOS III expression. The effect of Diabetes was considered significant
(p,0.05), the effect of L-Arg was not significant. *p,0.05 vs. control
untreated rats, #p,0.05 vs. control rats treated with L-Arg. Data are
mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0104923.g003
Figure 4. AQP2 expression in homogenates of the renal outer
medulla. A. Representative western blot analysis of AQP2 (28 and 35–
40 kDa bands; unglycosylated and glycosylated forms respectively) and
tubulin (50 kDa band) in the renal outer medulla. B. AQP2 expression
indicated as the ratio AQP2/tubulin fold change from control untreated
rats. Two-way ANOVA showed no statistically significant interaction
between the effects of Diabetes and L-Arg treatment on the expression
of AQP2. The effects of Diabetes and L-Arg on AQP2 expression were
considered very significant (p,0.01). **p,0.01 vs. control untreated
rats; ##p,0.01 vs. control rats treated with L-Arg, &&p,0.01 vs.
diabetic untreated rats. Data are mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0104923.g004
Figure 5. AQP2 mRNA levels in the renal outer medulla. AQP2
mRNA levels are expressed as relative values from control untreated
rats. The following formula was applied: DDCT = (CTAQP22CTGAPDH)
experimental2(CT AQP22CT GAPDH)control untreated rats. Two-way
ANOVA showed a statistically significant (p,0.001) interaction between
the effects of Diabetes and L-Arg treatment on AQP2 mRNA expression.
Bonferroni’s post- tests: *p,0.05 vs. control untreated rats; ***p,0.001
vs. control untreated rats; &&&p,0.001 vs. diabetic untreated rats. Data
are mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0104923.g005
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treatment of the animals with L-NAME suppressed the compen-
satory increase in AQP2 expression [48]. However, that study was
performed three weeks after the induction of diabetes and the
authors attributed the effect of L-NAME to the inhibition of
vasopressin release.
We showed that the increase in the expression of AQP2 mRNA
in the diabetic treated group is higher than in the control treated
group. However, the higher increase in the diabetic treated group
is not reflected at protein level. Numerous observations suggest
that AQP2 protein abundance is directly modulated via altered
expression of AQP2 mRNA. However, uncoupled expression
between AQP2 mRNA and protein has also been described under
certain conditions [49]. One explanation of the disparity between
AQP2 protein and mRNA expression could be the regulated
sequestration of mRNAs that lowers the amount of mRNA
available for translation [12,50]. These observations suggest that
AQP2 protein expression may be adjusted not only at the mRNA
level but also at a post-transcriptional level.
The present results suggest that the decreased expression and
activity of NOS in collecting ducts could be, at least in part, the
cause of the AQP2 decreased expression in this model of diabetes
induced by STZ. However, NO is known to be diuretic and
natriuretic via soluble guanylate cyclase/protein kinase G activa-
tion at the proximal tubule level [46]. A possible explanation for
these apparently contradictory findings is that at the level of the
collecting duct, where the fine tuning of urine composition occurs,
an increase in NO may enhance AQP2 in order to avoid an
excessive loss of water. In certain pathological states which trigger
the development of polyuria, such as diabetes, decreased NO
levels would lead to a reduction in the expression of AQP2 in
order to avoid an excessive loss of water.
Our results suggest that the decreased NOS activity in the
collecting ducts of the renal outer medulla may cause, at least in
part, the decreased expression of AQP2 at an early time point in
this model of diabetes and constitute additional evidence
supporting a role for NO in the contribution to renal water
reabsorption through the modulation of AQP2 expression in this
pathological condition.
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